ELM Advisors LLC bought a new position in Novartis AG (NYSE:NVS) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 475 shares of the company’s stock, valued at approximately $45,000.
Other large investors have also modified their holdings of the company. Rockbridge Investment Management LCC purchased a new position in shares of Novartis in the second quarter valued at about $25,000. Simon Quick Advisors LLC purchased a new position in shares of Novartis during the third quarter valued at approximately $26,000. TFC Financial Management purchased a new position in shares of Novartis during the third quarter valued at approximately $29,000. Northwest Investment Counselors LLC purchased a new stake in Novartis during the third quarter valued at approximately $33,000. Finally, JJJ Advisors Inc. increased its holdings in Novartis by 407.9% during the third quarter. JJJ Advisors Inc. now owns 386 shares of the company’s stock valued at $34,000 after buying an additional 310 shares during the last quarter. Institutional investors own 9.06% of the company’s stock.
Shares of NYSE NVS opened at $94.04 on Friday. The firm has a market cap of $215.23 billion, a PE ratio of 30.43, a PEG ratio of 1.96 and a beta of 0.58. The firm has a fifty day moving average of $90.86 and a 200 day moving average of $87.32. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.69 and a current ratio of 0.91. Novartis AG has a one year low of $69.18 and a one year high of $99.84.
Novartis (NYSE:NVS) last announced its quarterly earnings results on Sunday, November 1st. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.07. The firm had revenue of $12.26 billion for the quarter, compared to analysts’ expectations of $12.58 billion. Novartis had a net margin of 14.71% and a return on equity of 24.39%. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.41 EPS. On average, equities analysts predict that Novartis AG will post 5.81 EPS for the current fiscal year.
A number of equities analysts recently weighed in on the stock. Berenberg Bank assumed coverage on shares of Novartis in a research report on Tuesday, September 29th. They set a “buy” rating for the company. Oddo Bhf lowered shares of Novartis from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 23rd. BidaskClub raised shares of Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, January 5th. Morgan Stanley reissued an “overweight” rating on shares of Novartis in a research note on Friday. Finally, UBS Group reaffirmed a “buy” rating on shares of Novartis in a research note on Wednesday, November 25th. Three analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. Novartis presently has a consensus rating of “Hold” and a consensus price target of $114.00.
About Novartis
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products.
Read More: How to Use the MarketBeat Retirement Calculator
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).